TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02909465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Using Midazolam as a premedication for reducing ketamine-induced agitation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Using Haloperidol as a premedication for reducing ketamine-induced agitation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: distilled water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: distilled water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: distilled water
Study: NCT02498977

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Real time polymerase chain reaction (PCR) gene expression measurement

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Real time polymerase chain reaction (PCR) gene expression measurement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine
Description: Immunosuppression drugs as per protocol
Study: NCT04153565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
Study: NCT01913522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Study: NCT03300362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Saline placebo
Study: NCT00664365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK958108
Description: GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK958108
Description: GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Study: NCT02909465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is routinely used for all procedural sedation in the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is routinely used for all procedural sedation in the patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine is routinely used for all procedural sedation in the patients.
Study: NCT02238249

Intervention type: DRUG
Intervention: Alesion®
Description: Dry Syrup
Study: NCT04663165

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal surgery
Description: Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regenerative periodontal surgery
Description: Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
Study: NCT00199849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Plasmid DNA Cancer Vaccine
Description: NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Plasmid DNA Cancer Vaccine
Description: NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Plasmid DNA Cancer Vaccine
Description: NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
Study: NCT01442649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
Study: NCT01862497

Intervention type: DRUG
Intervention: Carvedilol vs. Prazosin

Intervention type: DRUG
Intervention: Carvedilol vs. Prazosin
Study: NCT00804505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
Description: Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Description: Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
Study: NCT01442649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m² on D1 every 2 weeks up to progression or toxicity
Study: NCT00762190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and insulin
Description: TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Study: NCT01285778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab, mytomicin C, 5-FU, radiation
Description: Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy.
Study: NCT05165641

Intervention type: PROCEDURE
Group type: OTHER
Intervention: segmental spinal anesthesia
Description: Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
Study: NCT04541329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: IL-23 inhibitor
Study: NCT03140540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEE guided fluid therapy will be administered
Description: Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke volume variation guided intravenous fluid.
Description: Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV \>10, 200 ml of colloid bolus to be given
Study: NCT02330185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: spinal anesthesia guided with ultrasonography
Study: NCT01259934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b - 1 year
Description: Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b - 2 years
Description: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
Study: NCT02936089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidation with auto-HSCT or HLA-matched HSCT
Description: For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic HSCT
Description: For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
Study: NCT02801461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study: NCT00617747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5mg Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04108741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mill augmented reality treadmill training
Description: PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill augmented reality treadmill training
Description: PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill augmented reality treadmill training
Description: PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
Study: NCT03412292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279
Description: MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses.
Study: NCT04120181

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study: NCT01516736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
Study: NCT04560556

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care (POC) Rapid HIV Test
Description: Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care (POC) Rapid HIV Test
Description: Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fourth Generation Antigen/antibody (Ag/Ab) HIV Test
Description: Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fourth Generation Antigen/antibody (Ag/Ab) HIV Test
Description: Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
Study: NCT01054495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser acupuncture
Description: A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
Study: NCT01465230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance lenalidomide
Description: Daily maintenance treatment, oral lenalidomide
Study: NCT04485663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-010133
Description: Single or multiple doses of ALG-010133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of Placebo
Study: NCT00389467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merci Retriever and Penumbra System
Description: The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2).
Study: NCT03999957

Intervention type: OTHER
Group type: OTHER
Intervention: Telehealth web conferencing
Description: Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
Study: NCT02849171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C-Choline
Study: NCT00620646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel
Description: aspirin 100 mg plus clopidogrel 150mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel, cilostazol
Description: aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
Study: NCT00572871

Intervention type: OTHER
Intervention: plyometric exercise
Description: single bout of plyometric exercise

Intervention type: OTHER
Intervention: resistance exercise
Description: single bout of resistance exercise

Intervention type: OTHER
Intervention: No exercise
Description: Will not do any exercise
Study: NCT04051697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEA CHANGE intervention
Description: The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
Study: NCT04529239

Intervention type: DEVICE
Intervention: Abbott Freestyle Libre Pro
Description: Continuous glucose monitoring device to analyze diabetes biomarkers.
Study: NCT03263247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alphabet search
Study: NCT03274453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.12 mg/kg/hr of ketamine post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.12 mg/kg/hr of ketamine post surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered at the same rate as the ketamine infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered at the same rate as the ketamine infusion.
Study: NCT03056651

Intervention type: OTHER
Group type: OTHER
Intervention: treatment in day-care heart failure unit